SFPI-FPIM
VC Fund
Brussels, Belgium
SFPI-FPIM is a VC fund in Brussels focused on Health Care and Biotechnology. The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries SFPI-FPIM invests in
Stages SFPI-FPIM invests in
Countries SFPI-FPIM invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.3M–$49M
- Series B
- $12M–$75M
- Venture - Series Unknown
- $2.7M–$51M
Investment Focus
Industry
- Health Care 12 (29%)
- Biotechnology 11 (26%)
- Medical 6 (14%)
- Medical Device 5 (12%)
- Pharmaceutical 5 (12%)
Stage
- Series B 9 (21%)
- Venture - Series Unknown 8 (19%)
- Series A 6 (14%)
- Series C 6 (14%)
- Series D 4 (10%)
Country
- Belgium 20 (48%)
- United States 2 (5%)
- The Netherlands 2 (5%)
- Spain 1 (2%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mr. Johan de Ketelbutter
Adviser-General
|
Adviser-General | Total investments: 0 | Find email | |
|
Mr. Koenraad Van Loo
CEO & Managing Director
|
CEO & Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies. | $250M / Series C / Feb 24, 2026 | ||
| Tangent Works operates as a data science startup.Tangent Works, the startup has automated the “repetitive” and “manual” parts of a data scientist’ job — namely, building the models. | $4.3M / Series A / Dec 15, 2022 | ||
| Cohabs is a network of beautiful shared homes for nomads around the world. It provides flexible and fully furnished accommodations through a network of sustainable and community-driven shared homes. Cohabs prioritizes the experience of its members through a tech-centric and flexible process. They build a thriving community through monthly events,dinners, and other parties. | $72.8M / Series C / Nov 16, 2022 | ||
| Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies. | $27M / Series A / Oct 25, 2022 | ||
| Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $43.3M / Series D / Oct 17, 2022 | ||
| Magnax valorizes yokeless axial flux technology in various markets. The company drives value by strategically investing to strengthen the position of its subsidiaries. These companies focus on specific markets, each requiring a unique approach. One is Traxial, which focuses on yokeless axial flux technology for ground-based e-mobility.www.traxial.com Our second subsidiary Axyal focuses on yokeless axial flux technology for aerospace www.axyal.com | $21.9M / Aug 23, 2022 | ||
| Magnax valorizes yokeless axial flux technology in various markets. The company drives value by strategically investing to strengthen the position of its subsidiaries. These companies focus on specific markets, each requiring a unique approach. One is Traxial, which focuses on yokeless axial flux technology for ground-based e-mobility.www.traxial.com Our second subsidiary Axyal focuses on yokeless axial flux technology for aerospace www.axyal.com | $19.9M / Venture - Series Unknown / Aug 23, 2022 | ||
| EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. | $51M / Venture - Series Unknown / Dec 24, 2021 | ||
| PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens.PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Françaisdu Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia.Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016. | $13.3M / Series B / Dec 06, 2021 | ||
| Qpinch’re committed to bringing their innovative chemical heat transformer to your plant and to helping your business save on energy bills while reducing your environmental footprint. | $16.6M / Series B / Sep 09, 2021 | ||
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SFPI-FPIM invest in?
SFPI-FPIM invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Venture - Series Unknown stage. Most of the 42 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SFPI-FPIM's check size?
SFPI-FPIM typically joins rounds of $4.3M–$49M at Series A, $12M–$75M at Series B and $2.7M–$51M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SFPI-FPIM participates in.
How do I contact SFPI-FPIM?
Public channels for SFPI-FPIM include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SFPI-FPIM?
The team at SFPI-FPIM includes Mr. Johan de Ketelbutter (Adviser-General) and Mr. Koenraad Van Loo (CEO & Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
